Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial

Carlo Zaninetti, Paolo Gresele, Antonella Bertomoro, Catherine Klersy, Erica De Candia, Dino Veneri, Serena Barozzi, Tiziana Fierro, Maria Adele Alberelli, Valeria Musella, Patrizia Noris, Fabrizio Fabris, Carlo L Balduini, Alessandro Pecci, Carlo Zaninetti, Paolo Gresele, Antonella Bertomoro, Catherine Klersy, Erica De Candia, Dino Veneri, Serena Barozzi, Tiziana Fierro, Maria Adele Alberelli, Valeria Musella, Patrizia Noris, Fabrizio Fabris, Carlo L Balduini, Alessandro Pecci

Abstract

Patients with inherited thrombocytopenias often require platelet transfusions to raise their platelet count before surgery or other invasive procedures; moreover, subjects with clinically significant spontaneous bleeding may benefit from an enduring improvement of thrombocytopenia. The hypothesis that thrombopoietin-mimetics can increase platelet count in inherited thrombocytopenias is appealing, but evidence is scarce. We conducted a prospective, phase II clinical trial to investigate the efficacy of the oral thrombopoietin-mimetic eltrombopag in different forms of inherited thrombocytopenia. We enrolled 24 patients affected by MYH9-related disease, ANKRD26-related thrombocytopenia, X-linked thrombocytopenia/ Wiskott-Aldrich syndrome, monoallelic Bernard-Soulier syndrome, or ITGB3-related thrombocytopenia. The average pre-treatment platelet count was 40.4 ×109/L. Patients received a 3- to 6-week course of eltrombopag in a dose-escalated manner. Of 23 patients evaluable for response, 11 (47.8%) achieved a major response (platelet count >100 ×109/L), ten (43.5%) had a minor response (platelet count at least twice the baseline value), and two patients (8.7%) did not respond. The average increase of platelet count compared to baseline was 64.5 ×109/L (P<0.001). Four patients with clinically significant spontaneous bleeding entered a program of long-term eltrombopag administration (16 additional weeks): all of them obtained remission of mucosal hemorrhages, with the remission persisting throughout the treatment period. Treatment was globally well tolerated: five patients reported mild adverse events and one patient a moderate adverse event. In conclusion, eltrombopag was safe and effective in increasing platelet count and reducing bleeding symptoms in different forms of inherited thrombocytopenia. Despite these encouraging results, caution is recommended when using thrombopoietinmimetics in inherited thrombocytopenias predisposing to leukemia. ClinicalTrials.gov identifier: NCT02422394.

Copyright© 2020 Ferrata Storti Foundation.

Figures

Figure 1
Figure 1
Mean increase in platelet count in the responders in part 1 of the study. Patients are categorized according to the diagnosis of the specific form of inherited thrombocytopenia. mBSS: monoallelic Bernard-Soulier syndrome; MYH9-RD: MYH9-related disease; . ANKRD26-RT: ANKRD26-related thrombocytopenia. XLT/WAS: X-linked thrombocytopenia/Wiskott-Aldrich syndrome. Mean values of platelet count at baseline and at the end of part 1 of the treatment along with their 95% confidence intervals (95%CI) are reported in the gray box.
Figure 2
Figure 2
Effects of treatments in part 1 and part 2 of the study in the four individuals who received long-term eltrombopag therapy. The figure summarizes the effects of eltrombopag administration on bleeding symptoms according to the World Health Organization (WHO) bleeding scale and on platelet count. Patients 1/1 and 12/10 have MYH9-related disease, patient 17/13 has ITGB3-RT, and patient 22/16 has Wiskott-Aldrich syndrome (see Table 5).

References

    1. Balduini CL, Pecci A, Noris P. Diagnosis and management of inherited thrombocytopenias. Semin Thromb Hemost. 2013; 39(2): 161–171.
    1. Orsini S, Noris P, Bury L, et al. Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. Haematologica. 2017; 102(7):1192–1203.
    1. Dupuis A, Gachet C. Inherited platelet disorders: management of the bleeding risk. Transfus Clin Biol. 2018; 25(3):228–235.
    1. Estcourt LJ, Birchall J, Allard S, et al. Guidelines for the use of platelet transfusions. Br J Haematol. 2017; 176(3):365–394.
    1. Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical prac-tice guideline from the AABB. Ann Intern Med. 2015; 162(3):205–213.
    1. Bolton-Maggs PH, Chalmers EA, Collins PW, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol. 2006; 135(5):603–633.
    1. Pecci A. Diagnosis and treatment of inherited thrombocytopenias. Clin Genet. 2016; 89(2):141–153.
    1. Rodeghiero F, Carli G. Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists. Ann Hematol. 2017; 96(9):1421–1434.
    1. Pecci A, Gresele P, Klersy C, et al. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood. 2010; 116(26): 5832–5837.
    1. Pecci A, Barozzi S, d’Amico S, Balduini CL. Short-term eltrombopag for surgical preparation of a patient with inherited thrombo-cytopenia deriving from MYH9 mutation. Thromb Haemost. 2012; 107(6):1188–1189.
    1. Favier R, Feriel J, Favier M, Denoyelle F, Martignetti JA. First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia. Pediatrics. 2013; 132(3):e793–795.
    1. Favier R, De Carne C, Elefant E, Lapusneanu R, Gkalea V, Rigouzzo A. Eltrombopag to treat thrombocytopenia during last month of pregnancy in a woman with MYH9-related disease: a case report. A A Pract. 2018; 10(1):10–12.
    1. Gröpper S, Althaus K, Najm J, et al. A patient with Fechtner syndrome successfully treated with romiplostim. Thromb Haemost. 2012; 107(3):590–591.
    1. Fiore M, Saut N, Alessi MC, Viallard JF. Successful use of eltrombopag for surgical preparation in a patient with ANKRD26-related thrombocytopenia. Platelets. 2016; 27(8):828–829.
    1. Westbury SK, Downes K, Burney C, et al. Phenotype description and response to thrombopoietin receptor agonist in DIAPH1-related disorder. Blood Adv. 2018; 2(18):2341–2346.
    1. Yamanouchi J, Hato T, Kunishima S, Niiya T, Nakamura H, Yasukawa M. A novel MYH9 mutation in a patient with MYH9 disorders and platelet size-specific effect of romiplostim on macrothrombocytopenia. Ann Hematol. 2015; 94(9);1599–1600.
    1. Gabelli M, Marzollo A, Notarangelo LD, Basso G, Putti MC. Eltrombopag use in a patient with Wiskott-Aldrich syndrome. Pediatr Blood Cancer. 2017; 64(12).
    1. Gerrits AJ, Leven EA, Frelinger AL, 3rd, et al. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood. 2015; 126(11):1367–1378.
    1. Noris P, Perrotta S, Seri M, et al. Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood. 2011; 117(24):6673–6680.
    1. Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood. 2010; 115(16):3231–3238.
    1. Massaad MJ, Ramesh N, Geha RS. Wiskott-Aldrich syndrome: a comprehensive review. Ann N Y Acad Sci. 2013; 1285:26–43.
    1. Noris P, Perrotta S, Bottega R, et al. Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombo-cytopenia derived from the monoallelic Ala156Val mutation of GPIb (Bolzano mutation). Haematologica. 2012; 97(1):82–88.
    1. Gresele P, Falcinelli E, Giannini S, et al. Dominant inheritance of a novel integrin β3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families. Haematologica. 2009; 94(5):663–669.
    1. Michelson AD, Barnard MR, Krueger LA, Frelinger AL, 3rd, Furman MI. Evaluation of platelet function by flow cytometry. Methods. 2000; 21(3):259–270.
    1. Pecci A. Pathogenesis and management of inherited thrombocytopenias; rationale for the use of thrombopoietin-receptor ago-nists. Int J Hematol. 2013; 98(1):34–47.
    1. Pecci A, Balduini CL. Lessons in platelet production from inherited thrombocytopenias. Br J Haematol. 2014; 165(2):179–192.
    1. Balduini CL, Savoia A, Seri M. Inherited thrombocytopenias frequently diagnosed in adults. J Thromb Haemost. 2013; 11(6):1006–1019.
    1. Rodeghiero F, Pecci A, Balduini CL. Thrombopoietin receptor agonists in hereditary thrombocytopenias. J Thromb Haemost. 2018; 16(9):1700–1710.
    1. Daskalakis M, Colucci G, Keller P, et al. Decreased generation of procoagulant platelets detected by flow cytometric analysis in patients with bleeding diathesis. Cytometry B Clin Cytom. 2014; 86(6):397–409.
    1. Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017; 130(23):2527–2536.
    1. Pecci A, Klersy C, Gresele P, et al. MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations. Hum Mutat. 2014; 35(2):236–247.
    1. Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplas-tic syndrome and thrombocytopenia. Cancer. 2014; 120(12):1838–1846.
    1. Platzbecker U, Wong RS, Verma A, et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocy-topenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. Lancet Haematol. 2015; 2(10):e417–426.
    1. Oliva EN, Alati C, Santini V, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombo-cytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017; 4(3):e127–e136.
    1. Mittelman M, Platzbecker U, Afanasyev B, et al. Eltrombopag for advanced myelodys-plastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol. 2018;(1):e34–e43.
    1. Dickinson M, Cherif H, Fenaux P, et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018; 132(25):2629–2638.
    1. Noris P, Favier R, Alessi MC, et al. ANKRD26-related thrombocytopenia and myeloid malignancies. Blood. 2013; 122(11): 1987–1989.
    1. Noris P, Pecci A. Hereditary thrombocytope-nias: a growing list of disorders. Hematology Am Soc Hematol Educ Program. 2017; 2017(1):385–399.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren